Therapeutic benefits in thalassemic mice transplanted with long-term-cultured bone marrow cells

Seigo Hatada, William Walton, Tomoko Hatada, Anne Wofford, Raymond Fox, Naiyou Liu, Michael C. Lill, Jeffrey Fair, Suzanne L. Kirby, Oliver Smithies

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Autologous bone marrow (BM) cells with a faulty gene corrected by gene targeting could provide a powerful therapeutic option for patients with genetic blood diseases. Achieving this goal is hindered by the low abundance of therapeutically useful BM cells and the difficulty maintaining them in tissue culture long enough to complete gene targeting without differentiating. Our objective was to devise a simple long-term culture system, using unfractioned BM cells, that maintains and expands therapeutically useful cells for ≥4 weeks. Materials and Methods: From 2 to 60 million BM cells from wild-type (WT) mice or from mice carrying a truncated erythropoietin receptor transgene were plated with or without irradiated fetal-liver-derived AFT024 stromal cells in 25-cm2 culture flasks. Four-week-cultured cells were analyzed and transplanted into sublethally irradiated thalassemic mice (1 million cells/mouse). Results: After 4 weeks, cultures with AFT024 cells had extensive "cobblestone" areas. Optimum expansion of Sca-1-positive cells was 5.5-fold with 20 × 106 WT cells/flask and 27-fold with 2 × 106 truncated erythropoietin receptor transgene cells. More than 85% of thalassemic mice transplanted with either type of cells had almost complete reversal of their thalassemic phenotype for at least 6 months, including blood smear dysmorphology, reticulocytosis, high ferritin plasma levels, and hepatic/renal hemosiderosis. Conclusions: When plated at high cell densities on irradiated fetal-liver-derived stromal cells, BM cells from WT mice maintain their therapeutic potential for 4 weeks in culture, which is sufficient time for correction of a faulty gene by targeting.

Original languageEnglish (US)
JournalExperimental Hematology
Volume39
Issue number3
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Bone Marrow Cells
Cultured Cells
Gene Targeting
Therapeutics
Erythropoietin Receptors
Stromal Cells
Transgenes
Liver
Reticulocytosis
Hemosiderosis
Inborn Genetic Diseases
Hematologic Diseases
Ferritins
Cell Count
Phenotype
Kidney

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Molecular Biology
  • Hematology

Cite this

Therapeutic benefits in thalassemic mice transplanted with long-term-cultured bone marrow cells. / Hatada, Seigo; Walton, William; Hatada, Tomoko; Wofford, Anne; Fox, Raymond; Liu, Naiyou; Lill, Michael C.; Fair, Jeffrey; Kirby, Suzanne L.; Smithies, Oliver.

In: Experimental Hematology, Vol. 39, No. 3, 03.2011.

Research output: Contribution to journalArticle

Hatada, S, Walton, W, Hatada, T, Wofford, A, Fox, R, Liu, N, Lill, MC, Fair, J, Kirby, SL & Smithies, O 2011, 'Therapeutic benefits in thalassemic mice transplanted with long-term-cultured bone marrow cells', Experimental Hematology, vol. 39, no. 3. https://doi.org/10.1016/j.exphem.2010.12.007
Hatada, Seigo ; Walton, William ; Hatada, Tomoko ; Wofford, Anne ; Fox, Raymond ; Liu, Naiyou ; Lill, Michael C. ; Fair, Jeffrey ; Kirby, Suzanne L. ; Smithies, Oliver. / Therapeutic benefits in thalassemic mice transplanted with long-term-cultured bone marrow cells. In: Experimental Hematology. 2011 ; Vol. 39, No. 3.
@article{99e38f8523a647659dfd87485ee6320a,
title = "Therapeutic benefits in thalassemic mice transplanted with long-term-cultured bone marrow cells",
abstract = "Objective: Autologous bone marrow (BM) cells with a faulty gene corrected by gene targeting could provide a powerful therapeutic option for patients with genetic blood diseases. Achieving this goal is hindered by the low abundance of therapeutically useful BM cells and the difficulty maintaining them in tissue culture long enough to complete gene targeting without differentiating. Our objective was to devise a simple long-term culture system, using unfractioned BM cells, that maintains and expands therapeutically useful cells for ≥4 weeks. Materials and Methods: From 2 to 60 million BM cells from wild-type (WT) mice or from mice carrying a truncated erythropoietin receptor transgene were plated with or without irradiated fetal-liver-derived AFT024 stromal cells in 25-cm2 culture flasks. Four-week-cultured cells were analyzed and transplanted into sublethally irradiated thalassemic mice (1 million cells/mouse). Results: After 4 weeks, cultures with AFT024 cells had extensive {"}cobblestone{"} areas. Optimum expansion of Sca-1-positive cells was 5.5-fold with 20 × 106 WT cells/flask and 27-fold with 2 × 106 truncated erythropoietin receptor transgene cells. More than 85{\%} of thalassemic mice transplanted with either type of cells had almost complete reversal of their thalassemic phenotype for at least 6 months, including blood smear dysmorphology, reticulocytosis, high ferritin plasma levels, and hepatic/renal hemosiderosis. Conclusions: When plated at high cell densities on irradiated fetal-liver-derived stromal cells, BM cells from WT mice maintain their therapeutic potential for 4 weeks in culture, which is sufficient time for correction of a faulty gene by targeting.",
author = "Seigo Hatada and William Walton and Tomoko Hatada and Anne Wofford and Raymond Fox and Naiyou Liu and Lill, {Michael C.} and Jeffrey Fair and Kirby, {Suzanne L.} and Oliver Smithies",
year = "2011",
month = "3",
doi = "10.1016/j.exphem.2010.12.007",
language = "English (US)",
volume = "39",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Therapeutic benefits in thalassemic mice transplanted with long-term-cultured bone marrow cells

AU - Hatada, Seigo

AU - Walton, William

AU - Hatada, Tomoko

AU - Wofford, Anne

AU - Fox, Raymond

AU - Liu, Naiyou

AU - Lill, Michael C.

AU - Fair, Jeffrey

AU - Kirby, Suzanne L.

AU - Smithies, Oliver

PY - 2011/3

Y1 - 2011/3

N2 - Objective: Autologous bone marrow (BM) cells with a faulty gene corrected by gene targeting could provide a powerful therapeutic option for patients with genetic blood diseases. Achieving this goal is hindered by the low abundance of therapeutically useful BM cells and the difficulty maintaining them in tissue culture long enough to complete gene targeting without differentiating. Our objective was to devise a simple long-term culture system, using unfractioned BM cells, that maintains and expands therapeutically useful cells for ≥4 weeks. Materials and Methods: From 2 to 60 million BM cells from wild-type (WT) mice or from mice carrying a truncated erythropoietin receptor transgene were plated with or without irradiated fetal-liver-derived AFT024 stromal cells in 25-cm2 culture flasks. Four-week-cultured cells were analyzed and transplanted into sublethally irradiated thalassemic mice (1 million cells/mouse). Results: After 4 weeks, cultures with AFT024 cells had extensive "cobblestone" areas. Optimum expansion of Sca-1-positive cells was 5.5-fold with 20 × 106 WT cells/flask and 27-fold with 2 × 106 truncated erythropoietin receptor transgene cells. More than 85% of thalassemic mice transplanted with either type of cells had almost complete reversal of their thalassemic phenotype for at least 6 months, including blood smear dysmorphology, reticulocytosis, high ferritin plasma levels, and hepatic/renal hemosiderosis. Conclusions: When plated at high cell densities on irradiated fetal-liver-derived stromal cells, BM cells from WT mice maintain their therapeutic potential for 4 weeks in culture, which is sufficient time for correction of a faulty gene by targeting.

AB - Objective: Autologous bone marrow (BM) cells with a faulty gene corrected by gene targeting could provide a powerful therapeutic option for patients with genetic blood diseases. Achieving this goal is hindered by the low abundance of therapeutically useful BM cells and the difficulty maintaining them in tissue culture long enough to complete gene targeting without differentiating. Our objective was to devise a simple long-term culture system, using unfractioned BM cells, that maintains and expands therapeutically useful cells for ≥4 weeks. Materials and Methods: From 2 to 60 million BM cells from wild-type (WT) mice or from mice carrying a truncated erythropoietin receptor transgene were plated with or without irradiated fetal-liver-derived AFT024 stromal cells in 25-cm2 culture flasks. Four-week-cultured cells were analyzed and transplanted into sublethally irradiated thalassemic mice (1 million cells/mouse). Results: After 4 weeks, cultures with AFT024 cells had extensive "cobblestone" areas. Optimum expansion of Sca-1-positive cells was 5.5-fold with 20 × 106 WT cells/flask and 27-fold with 2 × 106 truncated erythropoietin receptor transgene cells. More than 85% of thalassemic mice transplanted with either type of cells had almost complete reversal of their thalassemic phenotype for at least 6 months, including blood smear dysmorphology, reticulocytosis, high ferritin plasma levels, and hepatic/renal hemosiderosis. Conclusions: When plated at high cell densities on irradiated fetal-liver-derived stromal cells, BM cells from WT mice maintain their therapeutic potential for 4 weeks in culture, which is sufficient time for correction of a faulty gene by targeting.

UR - http://www.scopus.com/inward/record.url?scp=79951952758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951952758&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2010.12.007

DO - 10.1016/j.exphem.2010.12.007

M3 - Article

VL - 39

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 3

ER -